| abstract |
Tricyclic steroid hormone receptor nuclear modulating compounds having the formula (1), in which A represents a moiety selected from the group of formulas (2); B represents a remainder selected from the group of formulas (3); and the remainder of formula (4) represents a benzofused heterocycle that has a substituent that is not hydrogen in at least one of R1 to R3, wherein said benzofused heterocycle that possesses a substituent that is not hydrogen, is given by a group moiety of formulas (5); X and Y together represent -CH2-CH2-, -CH2-O-, or -O-CH2-; "the dotted line" represents a double union; R4 to R7 each independently represents hydrogen, hydroxy, halo, (C1-6) alkyl, (C1-6) alkoxy; or OR14, wherein R14 represents (C1-4) alkyl-aryl, aryl substituted with (C1-4) alkyl, (C1-4) alkyl-heterocycle, or (C1-4) -cycloalkyl (C3-7) alkyl ; R8 represents hydrogen, halo, (C1-6) alkyl, hydroxymethyl, (C1-4) alkyl-C1-6 alkoxy, or COR12 wherein R12 represents (C1-6) alkoxy; C3-7 cycloalkyl, phenyl, or substituted aryl; or a salt thereof acceptable for pharmaceutical use. Pharmaceutical composition comprising said compounds and a vehicle acceptable for pharmaceutical use. Its use for the manufacture of a medicament for the treatment of congestive diastolic or systolic cardiac arrest and hypertension. |